Individualized decision aid for diverse women with lupus nephritis (IDEA-WON): A randomized controlled trial
Authors: Jasvinder A Singh, Liana Fraenkel, Candace Green, Graciela S Alarcón, Jennifer L Barton, Kenneth G Saag, Leslie M Hanrahan, Sandra C Raymond, Robert P Kimberly, Amye L Leong, Elyse Reyes, Richard L Street Jr., Maria E Suarez-Almazor, Guy S Eakin, Laura Marrow, Charity J Morgan, Brennda Caro, Jeffrey A Sloan, Bochra Jandali, Salvador R Garcia, Jennifer Grossman, Kevin L Winthrop, Laura Trupin, Maria Dall’Era, Alexa Meara, Tara Rizvi, W Winn Chatham, Jinoos Yazdany
Journal: PLOS Medicine
Accepted: 2019-04-04T00:00:00Z

Background: Treatment decision-making regarding immunosuppressive therapy is challenging for individuals with lupus. We assessed the effectiveness of a decision aid for immunosuppressive therapy in lupus nephritis. Methods and findings: In a United States multicenter, open-label, randomized controlled trial (RCT), adult women with lupus nephritis, mostly from racial/ethnic minority backgrounds with low socioeconomic status (SES), seen in in- or outpatient settings, were randomized to an individualized, culturally tailored, computerized decision aid versus American College of Rheumatology (ACR) lupus pamphlet (1:1 ratio), using computer-generated randomization. We hypothesized that the co-primary outcomes of decisional conflict and informed choice regarding immunosuppressive medications would improve more in the decision aid group. Of 301 randomized women, 298 were analyzed; 47% were African-American, 26% Hispanic, and 15% white. Mean age (standard deviation [SD]) was 37 (12) years, 57% had annual income of <$40,000, and 36% had a high school education or less. Compared with the provision of the ACR lupus pamphlet (n = 147), participants randomized to the decision aid (n = 151) had (1) a clinically meaningful and statistically significant reduction in decisional conflict, 21.8 (standard error [SE], 2.5) versus 12.7 (SE, 2.0; p = 0.005) and (2) no difference in informed choice in the main analysis, 41% versus 31% (p = 0.08), but clinically meaningful and statistically significant difference in sensitivity analysis (net values for immunosuppressives positive [in favor] versus negative [against]), 50% versus 35% (p = 0.006). Unresolved decisional conflict was lower in the decision aid versus pamphlet groups, 22% versus 44% (p < 0.001). Significantly more patients in the decision aid versus pamphlet group rated information to be excellent for understanding lupus nephritis (49% versus 33%), risk factors (43% versus 27%), medication options (50% versus 33%; p ≤ 0.003 for all); and the ease of use of materials was higher in the decision aid versus pamphlet groups (51% versus 38%; p = 0.006). Key study limitations were the exclusion of men, short follow-up, and the lack of clinical outcomes, including medication adherence. Conclusions: An individualized decision aid was more effective than usual care in reducing decisional conflict for choice of immunosuppressive medications in women with lupus nephritis. Trial registration: Clinicaltrials.gov, NCT02319525. 
Jasvinder Singh and colleagues reveal how a decision aid helps women with lupus to make decisions about immunosuppressive therapy.
Why was this study done?:  What did the researchers do and find?:  What do these findings mean?: